Latest Breaking News On - Oncology development at astellas - Page 1 : comparemela.com

FDA Accepts BLA Resubmission for Zolbetuximab in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

Enzalutamide Receives Go Ahead From European Commission in nmHSPC

The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.

Japan's MHLW Approves Zolbetuximab in CLDN18.2-Positive Gastric Cancer

The Japanese Ministry of Health, Labour and Welfare has approved zolbetuximab for CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.

Japan Grants Priority Review to Enfortumab Vedotin/Pembrolizumab in First-Line Urothelial Carcinoma

The sNDA for enfortumab vedotin-ejfv plus pembrolizumab in patients with metastatic urothelial cancer has received priority review in Japan.

EMA Validates Application for First-Line Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

The type II variation application for enfortumab vedotin plus pembrolizumab in untreated metastatic urothelial cancer has been validated by the EMA.